Detection of Extended-spectrum ?-lactamases (ESBLS) Among Enterobacteriaceae Inside Departments of Sabha Medical Center Hospital, Especially Nursery Department and Outpatient of Sabha City , Fazzan Area in Southwestern of LIBYA
Keywords:
Enterobacteriaceae, Sabha, Nursery Department, outpatient, LIBYA.Abstract
To estimate a rate of spread of ESBL-producing Enterobacteriaceae among out and inpatient Sabha Medical Center in stool, urine samples. ESBLS activities were tested by the double disk synergy. The isolates were Escherichia coli 83(47.7%), 42(24.13%), Klebsiella spp. 21(12.0%), 11(6.3%), other type of Enterobacteriaceae 13(7.4%) 4(2.29%) for in and outpatient respectively. Forty four (25.28%) ESBLs strains were detected in 54.5%, 11.36% of E. coli, 15.9%, 4.5% of Klebsiella spp., 11.36%, 2.27%of other, for in and outpatient respectively. Prevalence rates 22.72%, 13.6%, 11.36 %, 9.09 % , 6.81% , 6.81 %,4.5% , 4.5% , 2.27% of ESBLs were isolated from patients on the Nursery, Medicine, surgery , Pediatric, Urology, Obstetric, Kidney Ward, ICU and ophthalmic department respectively. Fecal carriage of ESBLs is 34% 6.8% for in and outpatient. Our study has provided a first ESBLS screening for Enterobacteriaceae in Sabha Medical Center. Faecal ESBLS-producing Enterobacteriaceae for inpatient is referring to the weakly antimicrobial policy implemented in the hospital and the aware risk of the spread it in the community. ESBLS- E. infection is prominent in Urinary Tract Infection for Nursery department and seems demonstrates the outbreak state in the hospital.
References
[2] Y. Doi, Y.S. Park, J.I. Rivera, etal. “Community-associated extended-spectrum?-lactamase-producing Escherichia coli infection in the United States”. Clinical Infectious Diseases, vol. 56, pp. 641-8, Mar. 2013.
[3] M.M. D'Andrea, F. Arena, L. Pallecchi, G.M. Rossolini. “CTX-M-type ?-lactamases.a successful story of antibiotic resistance”. International Journal of Medical Microbiology, vol. 303, pp.305-17, Aug. 2013.
[4] C. Lascols, M. Hackel, A.M. Hujer, et al. “Using nucleic acid microarrays to perform molecular epidemiology and detect novel ?-lactamases. a snapshot of extended-spectrum ?-lactamases throughout the world” . Journal of Clinical Microbiology, vol. 50, pp.1632-9, May 2012.
[5] M. Gazin, F. Paasch, H. Goossens, et al. “Current trends in culture-based and molecular detection of extended-spectrum-?-lactamase-harboring and carbapenem-resistant Enterobacteriaceae” . Journal of Clinical Microbiology, vol. 50, pp. 1140-6, Apr .2012.
[6] P.L. Woerther, C. Burdet, E. Chachaty, A. Andremont. “Trends in human fecal carriage of extended-spectrum ?-lactamases in the community: toward the globalization of CTX-M”. Clinical Microbiology Review, vol. 26, pp. 744-58, Oct. 2013.
[7] A.M. Hammerum, J. Larsen, V.D. Andersen, et al. “Characterization of extended-spectrum ?-lactamase (ESBL)-producing Escherichia coli obtained from Danish pigs, pig farmers and their families from farms with high or no consumption of third- or fourth-generation cephalosporins”. Journal of Antimicrobial Chemotherapy, vol. 69, pp. 2650-7, Oct. 2014.
[8] H .Shi, F. Sun, J. Chen, etal. “Epidemiology of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing nosocomial - Escherichia coli infection in China”. Annals of Clinical Microbiology and Antimicrobials , vol. 14, pp.4, Jan. 2015, DOI 10.1186/s12941-015-0063-7.
[9] Clinical and Laboratory Standards Institute. (2015, Jan.) “Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement M100-S25”. Clinical and Laboratory Standards Institute, Wayne, PA. [on–line]. 35(3), http://shop.clsi.org/c.1253739/site/Sample_pdf/M100S25_sample.pdf: (Accessed on May 14, 2015).
[10] K.S. Thomson, E.S. Moland. “Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium”. Microbes and Infection, vol. 2, pp. 1225-35, Aug. 2000.
[11] A. A. Abujnah, A. Zorgani, M. A. M. Sabri, H. El-Mohammady, R. A. Khalek, K. S. Ghenghesh. “Multidrug resistance and extended-spectrum ?-lactamases genes among Escherichia coli from patients with urinary tract infections in Northwestern Libya”. Libyan Journal of Medicine, vol. 10, pp. 26412, Feb. 2015.
[12] K. S. Ghenghes , A. Rahouma, K. Tawil, A. Zorgani, E. Franka“ Antimicrobial resistance in Libya: 1970–2011” . Libyan Journal of Medicine, vol.8, pp. 20567, Mar.2013.
[13] J. Isendahl, A. Turlej-Rogacka, C. Manjuba, A. Rodrigues, C.G. Giske, P. Naucler, “ Fecal carriage of ESBL-producing E. coli and K. pneumoniae in children in Guinea-Bissau: a hospital-based crosssectional study” . PLoS ONE, vol. 7, pp. e51981, Dec. 2012.
[14] S. Ghafourian, Z. Sekawi, V. Neela, S. Khosravi, M. Rahbar N. Sadeghifard. “Incidence of extendedspectrum beta-lactamase-producing Klebsiella pneumoniae in patients with urinary tract infection”. Sao Paulo Medical Journal, vol. 130, pp. 37-43, 2012.
[15] S. Haller, C. Eller, and J. Hermes etal. “What caused the outbreak of ESBL-producing Klebsiella pneumoniae in a neonatal intensive care unit, Germany2009 to 2012? Reconstructing transmission with epidemiological analysis and whole-genome sequencing”. BMJ Open. Vol. 5, pp. e007397, Aug. 2015, doi:10.1136/bmjopen-2014-007397.
[16] N. O'Connell , D. Keating, J. Kavanagh, K. Schaffer. “Detection and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae in high-risk patients in an Irish tertiary care hospital”. The Journal of Hospital Infection, vol. 90, pp. 102-7, Jun. 2015. doi: 10.1016/j.jhin.
[17] A.F. Tawfik, A.M. Alswailem, Shibl, M.H. Al-Agamy. “Prevalence and genetic characteristics of TEM, SHV, and CTX-M in clinical Klebsiella pneumoniae isolates from Saudi Arabia”. Microbial Drug Resistance, vol. 17, pp. 383-8, Sep. 2011.
[18] K. S. Saroj, S. Hemalatha. “Extended spectrum Beta lactamase (ESBL) Mechanism of antibiotic resistance and Epidemiology”. International Journal of PharmTech Research, International Journal of Pharm Tech Research, vol. 7, pp. 303-309, 2014-2015, ISSN: 0974-4304.
[19] N.S. Fam , S. Defasque , F. Bert. “Faecal carriage of extended-spectrum ?-lactamase (ESBL)-producing enterobacteria in liver disease patients from two hospitals in Egypt and France: a comparative epidemiological study”. Epidemiology and Infection, vol. 143, pp. 1247-55, Apr. 2015. doi: 10.1017/S0950268814001812.
[20] M. Hilty, B.Y. Betsch, K. Bögli-Stuber. “Transmission dynamics of extended-spectrum?-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting”. Clinical Infection Disease, vol. 55, pp. 967-975, June 2012.
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.